Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

completed133%
not_yet_recruiting133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

NCT07490288
terminatedphase_2

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT01871441
completedphase_2

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

NCT01982682

Clinical Trials (3)

Showing 3 of 3 trials
NCT07490288Not Applicable

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

Not Yet Recruiting
NCT01871441Phase 2

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Terminated
NCT01982682Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3